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Velaglucerase alfa (VPRIV) enzyme replacement therapy in
patients with Gaucher disease: Long-term data from phase
III clinical trials
Derralynn A. Hughes,1,2* Derlis E. Gonzalez,3 Elena A. Lukina,4 Atul Mehta,1,2 Madhulika Kabra,5 Deborah Elstein,6
Isaac Kisinovsky,7 Pilar Giraldo,8,9 Ashish Bavdekar,10 Thomas N. Hangartner,11 Nan Wang,12 Eric Crombez,13
and Ari Zimran6
Type 1 Gaucher disease is an inherited lysosomal enzyme deficiency with variable age of symptom onset.
Common presenting signs include thrombocytopenia, anemia, hepatosplenomegaly, bone abnormalities, and,
additionally in children, growth failure. Fifty-seven patients aged 3–62 years at the baseline of two phase III
trials for velaglucerase alfa treatment were enrolled in the single extension study. In the extension, they
received every-other-week velaglucerase alfa intravenous infusions for 1.2–4.8 years at 60 U/kg, although 10
patients experienced dose reduction. No patient experienced a drug-related serious adverse event or
withdrew due to an adverse event. One patient died following a convulsion that was reported as unrelated
to the study drug. Only one patient tested positive for anti-velaglucerase alfa antibodies. Combining the
experience of the initial phase III trials and the extension study, significant improvements were observed in
the first 24 months from baseline in hematology variables, organ volumes, plasma biomarkers, and, in adults,
the lumbar spine bone mineral density Z-score. Improvements were maintained over longer-term treatment.
Velaglucerase alfa had a good long-term safety and tolerability profile, and patients continued to respond
clinically, which is consistent with the results of the extension study to the phase I/II trial of velaglucerase
alfa. EudraCT number 2008-001965-27; www.clinicaltrials.gov identifier NCT00635427.
Am. J. Hematol. 90:584–591, 2015. VC 2015 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc.
 Introduction
Gaucher disease (GD) is a rare genetic disease caused by mutations in GBA, which encodes a hydrolytic, lysosomal enzyme (glucosylceramidase).
When this enzyme is deficient, the major natural glucocerebroside substrates of the enzyme accumulate in cells, notably macrophages, which are
most responsible for the visceral pathophysiology in type 1 GD. Type 1 GD can present at variable ages with thrombocytopenia, anemia, hepatosple-
nomegaly, bone marrow infiltration, and various focal and generalized bone abnormalities, and additionally in children, with growth failure [1,2].
Current GD-specific treatment, enzyme replacement therapy (ERT) and substrate reduction therapy, is beneficial but not curative, and so
patients usually have regular continual dosing. Valuable research into disease outcomes, with and without treatment, has been conducted through
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GD registries [3–5]. There is, however, also a need for clinical trial
evidence for long-term drug efficacy and safety, and this should
include data in pediatric patients.
Velaglucerase alfa is available as an ERT for type 1 GD. Two
randomized, parallel-group phase III trials of velaglucerase alfa were
conducted between 2007 and 2009 in treatment-na€ıve patients,
including children: study identifiers TKT032 (a parallel assessment of
two doses) and HGT-GCB-039 (a noninferiority study comparing
velaglucerase alfa with imiglucerase). No patient discontinued from
these studies because of an adverse event (AE), and improvements in
hemoglobin concentration, platelet count, spleen volume, liver vol-
ume, biomarkers [6,7], and bone mineral density (BMD) were
observed. Patients who completed the initial trials were enrolled in an
open-label, phase III extension study for up to 5 years of follow-up,
to evaluate the long-term safety and efficacy of velaglucerase alfa.
 Patients and Methods
The extension study was an open-label study conducted between March 2008
and December 2012 into which patients who completed the trial TKT032 (53
weeks) or HGT-GCB-039 (41 weeks) were enrolled. As previously described, the
diagnosis of GD was confirmed by an enzyme assay (deficient leukocyte glucocere-
brosidase activity) before the TKT032 and HGT-GCB-039 trials, and patients’ geno-
types were analyzed [6,7].
Patients were ineligible to enroll into the extension study if they had a signifi-
cant comorbidity (e.g., malignancies, hepatic cirrhosis, autoimmune liver disease,
etc.); were pregnant, lactating, or unable to comply with the protocol; or had
received treatment with an investigational drug other than velaglucerase alfa in the
30 days before study entry.
Eleven clinical sites participated in one or both of the initial trials; nine sites in eight
countries enrolled patients into the extension study as well. Each site had the protocol,
protocol amendments, and patient consent forms approved by an independent ethics
committee or institutional review board. The study was conducted in compliance with
the International Conference on Harmonisation (ICH) Guideline for Good Clinical
Practice and the US Code of Federal Regulations, Title 21, Part 56. Each patient or their
legally authorized representative(s) gave written informed consent.
All patients received their first three infusions of the extension study at a clinical site.
If patients did not experience an infusion-related AE or drug-related serious AE, subse-
quent infusions could be administered at home by trained medical personnel per the dis-
cretion and direction of the investigator. An infusion-related AE was defined as an AE
that was considered related to the study drug and began within 12 hrs of the infusion.
In the trials TKT032 and HGT-GCB-039, patients were randomly assigned to
one of the two treatment arms; to maintain blinding, all patients who were enrolled
in the extension study after completing either of these trials were assigned 60 U/kg/
infusion of velaglucerase alfa regardless of the treatment or dose received in the ini-
tial trial. According to the extension study protocol, velaglucerase alfa was to be
administered in a 60-min intravenous infusion every other week (EOW).
Once patients completed a cumulative 24-month period of ERT from their first
infusion in the initial trial, investigators could increase or decrease their dose by 15
U/kg once every 12 months based on the achievement of therapeutic goals [8], but
each patient’s dose had to stay within the range of 15–60 U/kg.
Patients could continue to receive velaglucerase alfa in the extension study until
commercial velaglucerase alfa became available to them individually, in their
respective countries, or the study was terminated (patients for whom the drug was
not marketed in their country at the time that they left the study nonetheless con-
tinued to receive treatment through a charitable access program).
Although all patients were na€ıve to ERT at the start of the core studies, they received
different ERTs for the first 9 months. Therefore, two main analysis groups were prede-
fined for the safety and efficacy evaluations based on the drug received in the initial tri-
als: velaglucerase alfa or imiglucerase. No comparative analyses were performed.
Safety assessments. Patients were monitored continuously for AEs. Vital signs
were measured, and concomitant medication use was recorded at every infusion
visit (EOW). Approximately every 3 months, physical examinations were per-
formed, safety-related laboratory tests were conducted, and blood samples were
screened for the presence of anti-velaglucerase alfa antibodies using an electroche-
miluminescent bridge immunoassay. The antibody testing methods are described in
detail elsewhere [9,10], but in brief, if the antibody screening test was positive,
radioimmunoprecipitation and electrochemiluminescent assays were used to con-
firm the presence of immunoglobulin G (IgG) and IgE antibodies, respectively.
Samples that met confirmatory antibody-positive cut-point criteria were tested for
enzyme neutralizing activity using a neutralizing antibody assay.
A urine pregnancy test was carried out before every infusion in female patients
of child-bearing potential. If the test was positive, the infusion was to be held, and
the result confirmed with a serum human chorionic gonadotropin test. If the serum
result was also positive, the investigator was to contact the Shire medical monitor
to determine the appropriate course of action.
Efficacy assessments. Blood samples were taken approximately every 3 months
to measure hemoglobin concentration, platelet count, chemokine (CAC motif)
ligand 18 (CCL18) level, and chitotriosidase activity, and blood samples were taken
yearly for type I collagen telopeptides N- and C-terminal cross-links (NTx and
CTx; markers of bone turnover). CCL18 and chitotriosidase were measured accord-
ing to the methods described by Boot et al. [11] and Aguilera et al. [12], respec-
tively. CTx and NTx were measured using an enzyme-linked immunosorbent assay.
Patients underwent quantitative abdominal magnetic resonance imaging at
yearly intervals to assess their spleen and liver volumes. Organ volumes were meas-
ured by a single independent reviewer who was blinded to patient identity and the
timing of the imaging in relation to the study. The measurements were normalized
to the patient’s body weight (% BW). A spleen volume corresponding to 0.2% BW
or a liver volume corresponding to 2.5% BW was equal to 1 multiple of normal.
The BMD of the lumbar spine and the femoral neck was assessed in patients
over 18 years of age using dual-energy X-ray absorptiometry (DXA). Different
DXA scanners were used between patients and to address differences in calibrations
between various machines from the same manufacturer, the BMIL Quality Assur-
ance/Quality Control phantom (BioMedical Imaging Laboratory, Dayton, OH) [13]
was measured on all the scanners, and cross-calibration equations were developed.
Most scanners were made by Hologic, Inc. (Bedford, MA) and the others were
by GE Lunar (Madison, WI). A between-manufacturer calibration using published
cross-calibration equations derived from patient data [14,15] was carried out to
account for systematic differences between these manufacturers. GE Lunar BMD
values were translated into the Hologic scale.
Drifts in calibration (gradual trends up or down) can occur in individual scan-
ners over time, as can break points (jumps) because of machine repairs, for exam-
ple. To address this, longitudinal quality assurance data were collected from the
scanners, and corrective calculations were made if needed; an assumption of no
drift was made for any sites without data for their machines.
One reviewer at a central laboratory (Wright State University, Dayton, OH) ana-
lyzed the phantom and patient data; the reviewer was blinded to the treatment
each patient had received. The analysis was overseen and checked by another
reviewer.
A database of reference values by Hologic was used to convert BMD measure-
ments to Z- and T-scores. Sex- and race-specific reference values were used to cal-
culate Z-scores, whereas T-scores for all adults were based on Caucasian female
reference data [16]. Z-scores represent the number of standard deviations (SDs) dif-
ference from age-matched means, and T-scores represent the number of SDs differ-
ence from young normal means. The T-scores were used to categorize BMD
measurements as normal (T-score –1), osteopenic (>–2.5 to <–1), or osteopor-
otic (–2.5) [17].
Safety and efficacy analyses. The primary objective of the extension study was to
evaluate the long-term safety of velaglucerase alfa treatment. Safety results were
evaluated in all patients who received at least one dose of velaglucerase alfa in the
extension study. AEs were summarized in tables by type or category.
Efficacy data were analyzed in the efficacy analysis population, which was
defined as all patients who were enrolled in the extension study. During the exten-
sion study, two subjects were withdrawn following confirmation that they did not
have type 1 GD but were in fact carriers who had been misdiagnosed due to false-
positive laboratory test results. These two misdiagnoses have previously been
described [7]. It was then specified that the efficacy analysis population included
only the enrolled patients with type 1 GD. So, the carriers were included in the
safety analyses, but excluded from the efficacy analysis population.
The extension study population was split into two according to the study drug
received in the initial trial: one group who received imiglucerase in HGT-GCB-039
and one group who received velaglucerase alfa in either TKT032 or HGT-GCB-039
(Fig. 1).
Efficacy variables. The secondary objectives of the extension study were to eval-
uate the effects of velaglucerase alfa treatment on hemoglobin concentration, plate-
let count, and spleen and liver volumes (the primary efficacy variables). Plasma
chitotriosidase and CCL18 (GD biomarkers), serum markers of bone turnover,
BMD, and assessments of growth and development in patients under 18 years of
age were all evaluated as exploratory objectives (data specific to children are
reported elsewhere).
Summary statistics at protocol-defined time points were calculated. Mean
changes and mean percentage changes from baseline were also calculated, together
with 95% confidence intervals to assist interpretation. Baseline was defined as
before the first dose in the initial trials.
Mean changes at 24 months were calculated, and, to evaluate changes over the
entire study period, a longitudinal data analysis was also performed using linear
mixed models.
The linear mixed models took all available data into account and were adjusted
for age at baseline, the baseline value of the clinical variable, splenectomy status
(for platelet count only), and sex (for hemoglobin concentration only).
Intermittent missing data were imputed for the change-from-baseline analysis at
24 months: last observation carried forward for missing post-baseline data, and,
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while extremely rare, missing baseline data were replaced with the next available
measurement.
The BMD analyses were conducted in all adults, and then, since bisphospho-
nates affect bone turnover [18], they were repeated in the subset who were not
treated concomitantly with bisphosphonates. Summary statistics were calculated for
the CTx and NTx levels at baseline and post-baseline time points, and Pearson’s
correlation was used to investigate a potential linear relationship between BMD Z-
scores and CTx or NTx values.
 Results
Analysis groups
All 25 patients who participated in TKT032 were enrolled in the
extension study. Thirty-two of 34 patients who received at least one
ERT infusion in HGT-GCB-039 were enrolled in the extension study
(Fig. 1): 16 from each treatment arm of HGT-GCB-039.
All 57 patients received velaglucerase alfa in the extension study
(Table I). The 16 patients who received imiglucerase in HGT-GCB-
039 were the imiglucerase-to-velaglucerase alfa group. All other
patients received velaglucerase alfa in the initial trial, and they were
pooled and called the overall velaglucerase alfa group (Fig. 1); this
group of 41 patients included the two GD carriers who were excluded
from the efficacy analysis population.
Nineteen of 57 patients completed the extension study. Thirty-
eight patients discontinued from the study, mostly (34 patients) due
to the termination of the trial by the sponsor. Three patients with-
drew consent for personal reasons and one patient died.
Velaglucerase alfa and concomitant drugs
In the efficacy analysis population, the overall velaglucerase alfa
group (39 patients) received between 1.5 and 4.8 years of ERT with
velaglucerase alfa in the extension study (median time, 3.7 years).
The imiglucerase-to-velaglucerase alfa group received 1.2–4.1 years of
velaglucerase alfa treatment (median time, 3.6 years).
Eight of 39 patients in the overall velaglucerase alfa group and two
patients in the imiglucerase-to-velaglucerase alfa group had up to
three stepwise reductions in dose from 60 U/kg. In both groups, the
median dose received in the extension study was 60.0 U/kg per EOW
infusion (range, 38.0–60.5 U/kg).
Only one patient (overall velaglucerase alfa group) took pre-infu-
sion medication (diphenhydramine and dexamethasone) to prevent
an infusion reaction. Bisphosphonates were used during the initial
trial, the extension study, or both by four adults in the overall vela-
glucerase alfa group and by three adults in the imiglucerase-to-
velaglucerase alfa group.
The two GD carriers who were excluded from the efficacy analysis
population were included in the safety population, and they received
velaglucerase alfa for a total of 3.4 years and 3.1 years before they
were withdrawn from the extension study.
Safety (extension study)
Almost all patients experienced an AE during the extension study
(Table II). The vast majority of events were Grade 1 or 2 in intensity,
i.e., mild or moderate; 12 of 431 AEs reported in the overall velaglu-
cerase alfa group and nine of 189 AEs in the imiglucerase-to-
velaglucerase alfa group were graded severe.
Sixteen of 57 patients experienced AEs that were deemed possibly
or probably related to velaglucerase alfa treatment (Table II). Of the
56 drug-related AEs reported in total, the only events that were expe-
rienced by more than one patient were hypertension (two patients in
the overall velaglucerase alfa group) and headache (one patient in
each analysis group). The drug-related AEs of hypertension (two
events) were infusion-related.
Six of 57 patients experienced infusion-related AEs (Table II). The
percentage of patients experiencing infusion-related AEs in every 3-
month interval in the extension study was low or zero (Supporting
Information Fig. S1). In the imiglucerase-to-velaglucerase alfa group,
there was no change in infusion-related AEs around the time of
switching to velaglucerase alfa treatment (Supporting Information Fig.
S1). Sixteen of 57 patients had at least one home infusion during the
extension study. No infusion-related AEs happened during their
home infusions.
Nineteen serious AEs were reported (Supporting Information Table
SI), including a spontaneous first-trimester abortion in a patient with
a history of miscarriages and suspected anti-phospholipid syndrome
and a patient death following a convulsion. No serious AEs were con-
sidered to be related to velaglucerase alfa treatment.
Figure 1. Outline of the two initial trials and the extension study. Two of 34 patients treated in HGT-GCB-039 did not enroll in the extension study. The over-
all velaglucerase alfa group5patients from the three treatment arms outlined by a double line. The imiglucerase-to-velaglucerase alfa group5patients
from the treatment arm outlined by a dashed line. *Never received Gaucher disease-specific treatment or at least none received in the 30 months (TKT032)
or 12 months (HGT-GCB-039) before study entry. †Investigators could adjust doses within the range of 15–60 U/kg.
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The death reported was of a 6-year-old male patient (GBA
genotype F213I/F213I) from India who was 3 years old at the
time of enrollment into study HGT-GCB-039. Twelve days after
the last velaglucerase alfa infusion, the patient was reported to
have had involuntary movements and breathlessness; he then
stopped breathing and died while at home. The seizure and death
were considered by the investigator to be unrelated to velaglucer-
ase alfa and related to GD progression. The patient was diag-
nosed with type 1 GD by his treating physician, but experienced
seizures and gait disturbance during the study that may have
indicated type 3 GD. He participated in the extension study for
24 months.
Two patients became pregnant during the extension study. One
patient chose to continue velaglucerase alfa treatment and signed a
pregnancy informed consent form. The patient did not report any
AEs during the pregnancy, but infusions were discontinued less than
3 months after the pregnancy was confirmed because of the termina-
tion of the extension study (the patient started to receive infusions
again after velaglucerase alfa become commercially available in Rus-
sia); she delivered at 39 weeks, and the neonate was described as nor-
mal. One patient discontinued infusions when the pregnancy was
confirmed. The patient had a spontaneous first-trimester abortion
(not related to study drug) and resumed velaglucerase alfa infusions
approximately 2 months after the abortion. Two male patients
TABLE I. Efficacy Analysis Population Before First Dose in Initial Trials
Overall velaglucerase alfa (n5 39) Imiglucerase-to-velaglucerase alfa (n5 16)
Median age, years (range) 29 (6, 62) 26 (3, 58)
Children, n (%) 8 (21) 5 (31)
Male, n (%) 21 (54) 7 (44)
GBA genotype, n (%)
N370S/N370S 13 (33) 2 (13)
N370S/84GG 1 (3) 0
N370S/L444P 2 (5) 1 (6)
L444P/L444P 2 (5) 2 (13)
N370S/Other 13 (33) 6 (38)
L444P/Other 3 (8) 0
F213I/F213I 0 2 (13)
Other/Other 5 (13) 3 (19)
Splenectomy status, n (%)
Intact 30 (77) 6 (38)
Splenectomized 9 (23) 10 (63)
Chitotriosidase gene 24-base pair allele, n (%)
Wild-type gene 20 (51) 10 (63)
Heterozygous 18 (46) 5 (31)
Homozygous (enzyme deficient) 1 (3) 1 (6)
Efficacy variables, median (range)
Hemoglobin, g/dL 10.90 (7.1, 14.4)a 10.65 (8.1, 13.1)
Platelet count 3109/L 82.5 (13, 310) 190.5 (63, 430)
Spleen volume, MN 13.60 (4.8, 65.1)b 21.45 (3.1, 44.4)
Liver volume, MN 1.50 (0.8, 3.2)a 1.60 (0.7, 2.8)
Plasma chitotriosidase, nmol/mL/hrc 43,769 (12,678, 99,393)d 36,319 (11,330, 112,777)
Plasma CCL18, ng/mL 1,789.0 (731, 4,065) 1,799.5 (806, 5,902)
BMD Z-score, patients 18 years
Lumbar spine 21.73 (24.20, 0.78) 21.54 (22.68, 3.22)
Femoral neck 20.59 (22.77, 2.37) 1.71 (21.83, 4.49)
BMD T-score category, patients 18 years, n
Lumbar spine: OPO, OPN, NOR 11, 15, 5 3, 3, 5
Femoral neck: OPO, OPN, NOR 1, 10, 20 0, 1, 10
The genotyping methods used in the initial trials (for GBA and the chitotriosidase gene) have been described in Refs. [6,7].
a n5 38.
b n529.
c Chitotriosidase-deficient patients not included; laboratory measurement multiplied by two in patients heterozygous for the 24-base pair chitotriosidase
gene mutation.
d In addition to one chitotriosidase-deficient patient, one patient with low baseline activity (<5,000 nmol/mL/hr) was excluded from this group.
MN: multiple of normal; BMD: bone mineral density; OPO: osteoporosis; OPN: osteopenia; NOR: normal.
TABLE II. Extension Study AE Summary in Safety Population
Patient experience
Overall velaglucerase alfa (n5 41) Imiglucerase-to-velaglucerase alfa (n5 16)
Number of patients (%) Number of events Number of patients (%) Number of events
Any AE 38 (93) 431 15 (94) 189
1 drug-related AE 9 (22) 35 7 (44) 21
1 infusion-related AE 5 (12) 25 1 (6) 1
1 serious AE 6 (15) 11 4 (25) 8
Life-threatening AE 0 0
Death 0 1 (6)
1 serious and drug-related AE 0 0
Discontinued from study due to AE 0 0
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fathered children during the study; their female partners both deliv-
ered after full-term pregnancies, and the neonates were described as
healthy and normal.
There were no clinically significant trends in vital sign measure-
ments or physical examination findings that suggested an increased
risk of harm with velaglucerase alfa (data not shown).
Anti-velaglucerase alfa antibodies. One patient tested positive for
IgG anti-velaglucerase alfa antibodies in the extension study, which
was transient. The first positive test was at week 53 (end of study visit
for the initial trial and first dose in the extension study) and tests at
weeks 65, 77, and 89 were also positive; tests from week 101 until the
patient discontinued were negative. The sera had neutralizing activity,
but there were no changes in the patient’s hemoglobin concentration
or platelet count deemed to suggest altered drug efficacy, and no
drug-related AEs were reported. No other patients tested positive for
anti-velaglucerase alfa antibodies, including three patients who were
positive for anti-imiglucerase antibodies and switched to velaglucerase
alfa after 9 months of imiglucerase treatment [6].
Efficacy
0–24 months. The mean increase in hemoglobin concentration
was 2.75 g/dL (26%) in the overall velaglucerase alfa group, and there
was a 120% mean increase in the platelet count compared with base-
line; a 64% mean decrease in spleen volume and a 27% mean
decrease in liver volume were also observed. The mean levels of the
biomarkers chitotriosidase and CCL18 decreased by around 80%, and
the BMD Z-scores assessed at the lumbar spine and femoral neck
increased by means of 0.62 SD and 0.12 SD respectively, but the 95%
confidence interval around the mean change in the femoral neck Z-
score included zero (no statistically significant change). The results in
the imiglucerase-to-velaglucerase alfa group were similar (Supporting
Information Table SII).
At baseline, the median serum CTx and NTx levels in adults were
0.473 (range, 0.20–1.64) ng/mL and 12.5 (range, 6.5–41.2) nmol bone
collagen equivalents/L, respectively, in the overall velaglucerase alfa
group and 0.424 (range, 0.20–0.83) ng/mL and 10.5 (range, 6.5–17.8)
nmol bone collagen equivalents/L, respectively, in the imiglucerase-to-
velaglucerase alfa group. The mean CTx level increased in the overall
velaglucerase alfa group between baseline and 24 months, and then it
decreased slightly in subsequent months despite continued treatment
(statistical significance was not tested). The mean CTx level in the
imiglucerase-to-velaglucerase alfa group also increased at first, during
9 months of imiglucerase ERT, and then it returned to the baseline
level with subsequent velaglucerase alfa treatment in the extension
study. The trends in NTx levels were similar. No significant correla-
tion was found between levels of CTx and NTx and BMD Z-scores
(all P-values >0.05).
Longitudinal analysis. The results of this analysis also indicated
that there were significant clinical improvements in the first 24
months. Over longer-term treatment, the improvements were either
maintained or continued at an attenuated rate (Fig. 2).
 Discussion
Velaglucerase alfa had a good long-term safety profile overall that
was consistent with the phase I/II extension study of velaglucerase
alfa conducted in a group of 10 adult patients [19]. This study also
confirmed that infusions can be safely administered at home by quali-
fied and trained medical personnel.
Only one patient required pre-infusion medication, and only six
(11%) patients experienced an infusion-related AE during the exten-
sion study. The percentage of patients experiencing infusion-related
events seems to be highest in the first year of treatment and decreases
over time, which is similar to other ERTs [20,21].
In the group who switched to velaglucerase alfa when they enrolled
in the extension study, there was no increase in infusion-related AEs
around the time of switching. In fact, only one infusion-related AE
occurred in the 16 patients who switched to velaglucerase alfa over
1.2–4.1 years. Switching from imiglucerase to velaglucerase alfa has
been shown to be safe in previous reports, both in patients who tran-
sitioned without a break or dose reduction [10,22] and in those who
experienced a break or dose adjustment beforehand [23–25].
There was one death following a serious AE of convulsion that the
investigator considered related to GD progression and unrelated to
treatment. The patient was a 3-year-old male at time of enrollment
into the primary study, HGT-GCB-039, and he was 6 years of age at
time of death. The patient met the eligibility criteria at study entry, as
his treating physician diagnosed him as having type 1 GD. During
the course of study participation, the patient developed neurologic
symptoms that are suggestive of type 3 GD, and his GBA genotype,
F213I/F213I, is also consistent with type 3 GD [26]. Velaglucerase
alfa is under investigation for type 3 GD (ClinicalTrials.gov identifier
NCT01685216), but published clinical data in patients with type 3
GD are so far limited to a single case report [27].
Pregnancy was an exclusion criterion, and patients were required
to use a medically acceptable form of contraception during the exten-
sion study, but two patients in our analysis population became preg-
nant. One of these women continued receiving velaglucerase alfa
infusions during pregnancy. The physician determined that it was in
the patient’s best interest to continue infusions. The Shire medical
monitor determined that it would be acceptable for the patient to
continue infusions and remain in the study; the patient elected to do
so and signed a pregnancy informed consent form. The results of
these two women did not cause the sponsor to revise the risk-benefit
profile of velaglucerase alfa, which, under the US Food and Drug
Administration pregnancy categories, is a Category B drug (“animal
reproduction studies have failed to demonstrate a risk to the fetus
and there are no adequate and well-controlled studies in pregnant
women”) [28,29]. We know that other women with GD have used
velaglucerase alfa in pregnancy; in a retrospective record review of 21
women and 25 pregnancies, no safety signals were identified [30].
One of the 57 patients tested positive for anti-drug antibodies,
which suggests that developing antibodies against velaglucerase alfa is
uncommon. An apparently low immunogenic potential has also been
found in other velaglucerase alfa trials [10,19]. The percentages of
patients who have developed anti-drug antibodies with other
approved ERTs are 15% [31] or, in taliglucerase alfa trials in type 1
GD patients, 53% and 13%. However, various factors, including assay
sensitivity and specificity, timing of sampling, underlying disease, and
concomitant medication, can affect antibody test results. So, the inci-
dences of antibody production associated with each drug may not be
comparable [32].
The patient who tested positive for anti-velaglucerase alfa antibod-
ies was transiently positive; there was no apparent effect on the clini-
cal efficacy of velaglucerase alfa, even though the patient’s sera were
reported as having neutralizing activity, and no drug-related AEs
were reported. The clinical relevance of developing anti-ERT (includ-
ing velaglucerase alfa) antibodies is unknown.
The primary efficacy variable findings indicated that patients con-
tinued to respond to ERT in the extension study. Levels of plasma
chitotriosidase and CCL18 both decreased over time, reflecting an
ongoing fall in the total burden of Gaucher cells in the body [11,33].
These biomarkers are being investigated for their potential to predict
long-term clinical complications, such as osteonecrosis [34,35].
Lumbar spine BMD Z-scores in adults improved by 24 months,
which was encouraging given the prevalence of osteopenia in the GD
population and retrospective registry-based research suggesting a
greater risk of spinal and nonspinal fractures with lumbar spine
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Z-scores –1 compared with Z-scores >–1 [36,37]. BMD was also
assessed as an exploratory variable in the phase I/II study of velaglu-
cerase alfa, and there was consistent improvement over time [38]. In
this study, mean Z-score changes in the femoral neck were much
smaller than in the lumbar spine (and without nominal significance),
but also, most patients (>64%) at baseline were no more than 1 SD
Figure 2. Mean changes and mean percentage changes in efficacy variables over time estimated from linear mixed models. Changes compared with base-
line (BL) values are plotted (baseline was before the first dose in the initial trials). Error bars show 95% confidence intervals. Dotted line at 9 months indi-
cates the time that the imiglucerase-to-velaglucerase alfa group switched to ERT with velaglucerase alfa. BMD: bone mineral density.
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below peak bone density at the femoral neck, which is considered
normal.
Although the changes in BMD suggest bone remodeling, there was
no significant correlation between BMD Z-scores and the CTx and
NTx values. This may have been because of the wide range of ages in
the analysis population, from young adults with developing bone
mass to postmenopausal women and elderly men. The attrition in
patient numbers after 24 months and the use of bisphosphonates by
some patients may also have affected the results.
To the best of our knowledge, this is the first time in a study of
GD that a cross-calibration of DXA scanners has been done. Cross-
calibration reduces differences between the BMD measurements of
different scanners [39]. In this study, multiple scanners made by two
different manufacturers were used. The cross-calibration enabled the
calculation of average absolute changes in BMD as well as the conver-
sion of the BMD data to Z-scores based on a single database of refer-
ence values. BMD values can be converted to Z- and T-scores using
manufacturer-specific reference datasets, but the scores obtained from
different manufacturers’ systems are not always comparable [40–42].
Ten patients had their dose reduced at least once. Zimran et al.
[19] reported continued clinical improvements in the phase I/II study
of velaglucerase alfa despite dose reduction in almost all patients. Less
than one-fifth of patients had their dose reduced in this study. None
of them subsequently had their dose increased, but the duration of
follow-up after dose reduction was different between patients and,
although dose adjustments were permitted per the study protocol,
this study was not designed to evaluate dosing variation. According
to the standards of care, the recommended starting dose of velaglu-
cerase alfa for ERT-na€ıve patients is 60 U/kg (and patients switching
from imiglucerase can be switched to the same U/kg dose) [29].
Study limitations
All patients received at least 24 months of ERT, but relatively few
patients reached 60 months. Because there were fewer subjects at later
time points, the longer-term data set was incomplete.
The cross-calibration of DXA scanners was post hoc; nonetheless,
with available longitudinal phantom data, adequate cross-calibration
was possible for the duration of the study. Cross-calibration was con-
sidered necessary to pool study data that had been collected from
multiple centers and increases the likelihood of detecting a possible
treatment effect. Where sites were missing quality assurance data for
their machines, an assumption of no drift (up or down) was made,
and this may have affected the accuracy of the DXA results.
Several efficacy assessments were exploratory; although they sup-
ported the direction of the results in hemoglobin concentration, plate-
let count, spleen volume, and liver volume and also provide
information for future research, they have less evidentiary value.
 Conclusion
Velaglucerase alfa had a good safety and tolerability profile in this
long-term study, and patients continued to demonstrate a satisfactory
clinical response. This is consistent with the data reported from the
extension study of the phase I/II trial.
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